Multiple Breath Washout (MBW) to measure Lung Clearance Index (LCI) is increasingly being used as a secondary endpoint in multicentre bronchiectasis studies. Data quality control or "over-reading" of LCI data ensures data validity and quality and some industry sponsored clinical trials have adopted this practice. However, over-reading is resource intensive and there are no studies in bronchiectasis examining the impact of overreading on data quality.
Introduction
Lung Clearance index (LCI) is the most commonly reported multiple breath washout (MBW) parameter. It has good clinimetric properties as an outcome measure and has been adopted as a surrogate endpoint in cystic fibrosis (CF) clinical trials (1) (2) (3) (4) . LCI is also being used in multicentre bronchiectasis studies as it has been shown to have good intravisit repeatability with better sensitivity in detecting lung disease on CT scan compared to FEV1 (5) (6) (7) . Much effort has been made to improve standardisation of MBW training, testing and analyses (8) (9) (10) (11) (12) . Accurate estimation of LCI and other MBW parameters depends on correct operation of the device and appropriate analysis and interpretation of the collected data. Acquisition of good quality MBW data can be influenced by operator training, competence and experience in testing and reporting of the data.
MBW test results from different devices are not interchangeable and standardization of the device used is required in multicenter studies (13) . However, even with standardization of the device, differences in software settings, patient interface dead space, breathing pattern protocols and operator technical expertise can all impact on results (12, 14, 15) . Central coordination and data quality control or "over-reading" service could improve standardisation in testing and reporting of the data to a research quality standard in accordance with consensus statement guidance (8) .
An over-reading protocol, to systematically evaluate MBW measurements for technical elements and stability of the breathing pattern, has been used in children with CF. The impact of the protocol on inter-observer agreement and reported MBW outcomes was assessed across 8 MBW operators from 4 institutions. Overall, use of the protocol resulted in improved inter-observer agreement but no change in reported MBW outcomes after over-reading. In 50 MBW tests (25 healthy children and 25 children with CF), application of an over reading protocol resulted in the rejection of 16.6% for technical reasons and a further 10.7% due to inappropriate breathing pattern. (9) . Over-reading in longitudinal studies was highlighted as important consideration, as the variability of the outcome within and between subjects will affect interpretation. In a multicentre study of 183 CF patients and 136 healthy volunteers from 8 centres, 24% of measurements in both groups were excluded due to quality issues (16) .
This study emphasised the importance of site training and a central over-reading process in multicentre studies. More recently, central training and assessment of MBW tests in CF preschool children and infants, reported high rates test success (91.8%) (17) .
These studies underline the importance of central over-reading for results accuracy in the multicentre setting in CF. However, over-reading of MBW data is resource intensive and significantly increases study costs. Currently there are no studies on the impact of central over-reading for MBW testing in the adult bronchiectasis population. In this study, we hypothesise that a central over-reading process in a multicentre bronchiectasis study will improve MBW result accuracy.
Aim
To determine the impact of central MBW over-reading in the bronchiectasis multicentre clinical study setting using data collected in the BRONCH-UK Clinimetrics study (ClinicalTrials.gov Identifier: NCT02468271). The impact of site MBW experience, length of sites current MBW testing activity and patient clinical status during MBW testing on the outcome of over-reading was also assessed. All sites completed a certification process before collecting MBW data in the study.  To assess the change in LCI (no. turnovers), LCI CV% and VT CV% in the first 12 months of site MBW study activity versus the second 12 months of site MBW testing activity.
 To assess the change in LCI (no. turnovers), LCI CV% and VT CV% in clinically stable versus pulmonary exacerbation MBW tests.
Methods
The BRONCH-UK Clinimetrics study is a prospective cohort study to determine the utility of a range of outcome measures including LCI, in clinical trials in bronchiectasis (https://www.bronch.ac.uk/clinimetrics-study; ClinicalTrials.gov Identifier: NCT02468271).
During the study, patients performed a MBW test in up to 6 study visits over a 24 month period (including 4 clinically stable and 2 exacerbation study visits). The study is currently on-going and data collected from November 2015 to July 2017 were used in this study. The data collected were from five UK sites, trained and certified in MBW testing in the bronchiectasis patient population. Three of the sites were previously naive to MBW testing (sites 2, 3, 4) and 2 sites were MBW expert sites (sites 1, 5). A Multiple Breath Nitrogen Washout (MBN2W) test was performed using the Ecomedics Exhalyzer® D (Spiroware software version 3.1.6) and a published Standard Operating Procedure (SOP) developed for CF by Jensen and working group (http://lab.research.sickkids.ca/ratjen/mbw-centre/). Patients performed at least 3 trials during which they breathed 100% oxygen during tidal breathing until N2 was washed out to <2.5% for at least 3 consecutive breaths. Sites followed quality control steps as detailed in the SOP (http://lab.research.sickkids.ca/ratjen/mbw-centre/) in addition to using quality control feedback provided by the Spiroware software (appendix 1). After the study visit, sites sent MBW data to the central over-reading facility in Belfast. Each test was assessed for validity and quality by a trained "over-reader" (KO'N, KF, DC) (appendix 2), using pre-defined technical (signal misalignment, leak, did not meet end of test criteria, N2 did not return to baseline between trials) and qualitative (repeatable testing session which reflects tidal breathing) criteria (9) . Troubleshooting teleconferences between over-readers in Belfast and 1-2 independent over-reader(s) from the Royal Brompton London convened monthly to discuss and compare over-reading practice in accordance with criteria. Questionable tests were assessed by the group and inter-rater agreement sought.
To derive a LCI result, a minimum of 2 technically valid and repeatable trials which represented tidal breathing were required. Tests with ≥3 trials are required to calculate LCI CV% and VT CV% in accordance with analysis guidelines in the inert gas washout consensus statement (8) . Values for LCI, LCI CV% and VT CV% before and after over-reading were recorded. Only those tests with a LCI value before and after over-reading (i.e. deemed to have a minimum of 2 technically valid and repeatable trials which represented tidal breathing) could be included in the comparison of LCI, LCI CV% and VT CV% before and after over-reading (i.e. those deemed not to meet this criteria either by the site or the over-reader did not have matching data). Only MBW tests with data before and after over-reading were included in the subsequent analysis. Before analysis, the data underwent a data cleaning process, where all entries were checked against source data (original spx. MBW data file) for accuracy.
Statistical analyses were conducted using SPSS version 22 (IBM Corporation, Somers, New York, USA). As the database contained multiple entries from individual patients, the mean ratio of LCI, LCI CV% and VT CV% values before and after over-reading was calculated for analysis. Mean ratios were log transformed to facilitate analysis and simple ttests were performed on the log ratios to test the null hypothesis of no effect i.e. no change in LCI, LCI CV% and VT CV% with over-reading. Sub group analysis of logged mean ratios of LCI, LCI CV% and VT CV% were used to assess for differences based on expert MBW site which were suitable for subsequent analysis (matched data before and after over-reading).
One hundred and fifty one tests had 3 or more trials and therefore had a LCI CV% and a VT CV% available for analysis.
The change in LCI, LCI CV% and VT CV% with over-reading in these tests was not statistically significant (Table 1) . 
Recognition of leak:
 Sudden spike in N2 signal.  Deviation in N2, O2 or CO2 signals inconsistent with phase of breath.  Sudden step change in volume trace.  Rise in N2 signal early in expirogram.
Action on recognition of leak:
 Stop trial.  Check patient positioning, mouthpiece and nose clip.  Check fitting of patient interface components.  Repeat trial after patient rest and when N2 returned to baseline.
Did not meet end of test criteria
Recognition of successful end of test:  ≥ 3 breaths < 2.5% N2.  All 3 breaths reflective of tidal breathing.
N2 not returned to baseline
Recognition of N2 not returned to baseline:
 End tidal N2 ≥77% at start of first trial and within 1.5% of baseline on subsequent trials. 
